<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163900</url>
  </required_header>
  <id_info>
    <org_study_id>NuTide:121</org_study_id>
    <secondary_id>2019-001025-28</secondary_id>
    <nct_id>NCT04163900</nct_id>
  </id_info>
  <brief_title>Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer</brief_title>
  <acronym>NuTide:121</acronym>
  <official_title>A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuCana plc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuCana plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in
      patients with previously untreated advanced biliary tract cancer.

      The primary hypotheses are:

        -  The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the
           gemcitabine plus cisplatin standard of care

        -  The combination of NUC-1031 plus cisplatin increases overall response rate compared to
           the gemcitabine plus cisplatin standard of care
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization model to either Arm A or Arm B</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Imaging scans will be assessed by blinded independent review according to RECIST v1.1</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Evaluated on an ongoing basis from randomization, then every 12 weeks from the date of treatment discontinuation until the date of death from any cause, up to a maximum of 18 months after the last patient starts treatment</time_frame>
    <description>The median time, in months, from the date of randomization to the date of death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Evaluated every 9 weeks from start of treatment or, where treatment is stopped with no evidence of progression, every 12 weeks until disease progression or death from any cause, up to a maximum of 18 months after the last patient starts treatment.</time_frame>
    <description>Percentage of patients achieving a confirmed complete or partial response to treatment as assessed by blinded independent review according to RECIST v1.1 criteria in patients with measurable disease at baseline. Patients will receive a confirmatory scan 28-42 days after response is first observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Evaluated every 9 weeks from start of treatment or, where treatment is stopped with no evidence of progression, every 12 weeks until disease progression or death from any cause, up to a maximum of 18 months after the last patient starts treatment</time_frame>
    <description>Based on blinded independent review according to RECIST v1.1 criteria and defined as the time from randomization to the first observation of objective tumour progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Evaluated every 9 weeks from initial clinical response or, where treatment is stopped with no evidence of progression, every 12 weeks until disease progression or death from any cause, up to a maximum of 18 months after the last patient starts treatment</time_frame>
    <description>Defined as the time from initial clinical response to the first observation of tumour progression or death from any cause as assessed by blinded independent review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month survival</measure>
    <time_frame>12 months from randomization</time_frame>
    <description>Proportion of patients still alive at 12 months from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18-month survival</measure>
    <time_frame>18 months from randomization</time_frame>
    <description>Proportion of patients still alive at 18 months from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Evaluated every 9 weeks from start of treatment or, where treatment is stopped with no evidence of progression, every 12 weeks until disease progression or death from any cause, up to a maximum of 18 months after the last patient starts treatment</time_frame>
    <description>Based on blinded independent review according to RECIST v1.1, defined as the percentage of patients demonstrating a Best Overall Response of Complete Response, Partial Response or Stable Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Adverse events that occur from initiation of therapy until 30 day post-treatment will be recorded. Adverse events that are not resolved at this time will be followed until resolution to baseline value.</time_frame>
    <description>Safety and tolerability will be assessed by total incidence of Treatment Emergent Adverse Events (TEAEs) according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only</measure>
    <time_frame>Day 1 of Cycle 1 (each cycle is 21 days): Blood samples taken within 10 minutes post-end of infusion, 2 hours post-end of infusion (±30 minutes) and 6 hours post-end of infusion (±30 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only</measure>
    <time_frame>Day 1 of Cycle 1 (each cycle is 21 days): Blood samples taken within 10 minutes post-end of infusion, 2 hours post-end of infusion (±30 minutes) and 6 hours post-end of infusion (±30 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t½) of NUC-1031, dFdC and dFdU using descriptive statistics in Arm A only</measure>
    <time_frame>Day 1 of Cycle 1 (each cycle is 21 days): Blood samples taken within 10 minutes post-end of infusion, 2 hours post-end of infusion (±30 minutes) and 6 hours post-end of infusion (±30 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz) of NUC-1031, dFdC and dFdU using descriptive statistics in Arm A only</measure>
    <time_frame>Day 1 of Cycle 1 (each cycle is 21 days): Blood samples taken within 10 minutes post-end of infusion, 2 hours post-end of infusion (±30 minutes) and 6 hours post-end of infusion (±30 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only</measure>
    <time_frame>Day 1 of Cycle 1 (each cycle is 21 days): Blood samples taken within 10 minutes post-end of infusion, 2 hours post-end of infusion (±30 minutes) and 6 hours post-end of infusion (±30 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of NUC-1031, dFdC and dFdU will be compared to existing data using simulations in Arm A only</measure>
    <time_frame>Day 1 of Cycle 1 (each cycle is 21 days): Blood samples taken within 10 minutes post-end of infusion, 2 hours post-end of infusion (±30 minutes) and 6 hours post-end of infusion (±30 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient-reported quality of life (QoL) scores in Arm A and Arm B</measure>
    <time_frame>Assessed at screening, on Day 1 of every cycle (each cycle is 21 days), and 30 days post-treatment</time_frame>
    <description>Assessed using the European Organisation for Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ-C30) using the QLQ-BIL21 module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient-reported quality of life (QoL) scores in Arm A and Arm B</measure>
    <time_frame>Assessed at screening, on Day 1 of every cycle (each cycle is 21 days), and 30 days post-treatment</time_frame>
    <description>Assessed using the 5-level EuroQol five-dimension scale (EQ-5D-5L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">828</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>A - NUC-1031 and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - gemcitabine and cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg/m^2 gemcitabine administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NUC-1031</intervention_name>
    <description>IV infusion in 500 mL of 0.9% sterile saline for injection given over 30 minutes</description>
    <arm_group_label>A - NUC-1031 and cisplatin</arm_group_label>
    <other_name>fosgemcitabine palabenamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion in 250 mL of 0.9% sterile saline for injection given in accordance with the package insert</description>
    <arm_group_label>B - gemcitabine and cisplatin</arm_group_label>
    <other_name>Difluorodeoxycytidine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV in accordance with local institutional practice for biliary tract cancer, including the use of an appropriate hydration protocol</description>
    <arm_group_label>A - NUC-1031 and cisplatin</arm_group_label>
    <arm_group_label>B - gemcitabine and cisplatin</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent and authorization to use and disclose health information.

          2. Ability to comprehend and willingness to comply with the requirements of this
             protocol, including the QoL questionnaires.

          3. Female or male patients aged ≥18 years.

          4. Histologically- or cytologically-confirmed adenocarcinoma of the biliary tract
             (including gallbladder, intra and extra-hepatic biliary ducts and ampullary cancers)
             that is locally advanced, unresectable or metastatic. Patients with measurable (as per
             RECIST v1.1 criteria) or non-measurable disease are permitted.

          5. Life expectancy ≥16 weeks.

          6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          7. Adequate biliary drainage with no evidence of ongoing infection. If applicable,
             treatable and clinically-relevant biliary duct obstruction has been relieved by
             internal endoscopic drainage/stenting at least 2 weeks previously or by palliative
             bypass surgery or percutaneous drainage prior to study treatment, and the patient has
             no active or suspected uncontrolled infection. Patients fitted with a biliary stent
             should be clinically stable and free of signs of infection for ≥2 weeks prior to study
             treatment. Patients with improving biliary function who meet all other inclusion
             criteria may be re-tested during the screening window.

          8. Adequate bone marrow, hepatic, and renal function, as evidenced by:

               -  Absolute neutrophil count (ANC) ≥1,500/μL without colony-stimulating factor
                  support

               -  Platelet count ≥100,000/μL

               -  Haemoglobin ≥10 g/dL without need for haematopoietic growth factor or transfusion
                  support in prior 2 weeks

               -  Total bilirubin &lt;2 × upper limit of normal (ULN); does not apply to patients with
                  Gilbert's syndrome. Consistent with inclusion criterion 7, patients whose whole
                  bilirubin and biliary function is recovering may be re-tested during the
                  screening period.

               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &lt;5 × ULN

               -  Creatinine clearance ≥45 mL/min actual or calculated by the Cockcroft-Gault
                  method

               -  International normalized ratio (INR) &lt;1.5 and partial thromboplastin time (PTT)
                  &lt;1.5 × ULN; does not apply to patients on an anti-coagulant with stable dose 28
                  days prior to first dose.

          9. QTc interval &lt;450 msec (males) or &lt;470 msec (females), in the absence of bundle branch
             block. In the presence of bundle branch block with consequent QTc prolongation,
             patients may be enrolled based on a careful risk-benefit assessment.

         10. Human Immunodeficiency Virus-infected patients who are healthy and have a low risk of
             Acquired Immunodeficiency Syndrome-related outcomes may be included in this study.

         11. Female patients of child-bearing potential (i.e., all women except those who are
             post-menopausal for ≥1 year or who have a history of hysterectomy or surgical
             sterilization) must have a negative pregnancy test within 3 days prior to the first
             study drug administration. All patients of child-bearing potential must agree to
             practice true abstinence or to use two highly effective forms of contraception, one of
             which must be a barrier method of contraception, from the time of screening until 6
             months after the last dose of study medication.

         12. Male patients with a female partner must either have had a successful vasectomy or
             they and their female partner meet the criteria above (not of childbearing potential
             or practicing highly effective contraceptive methods).

        Exclusion Criteria:

          1. Combined or mixed hepatocellular/cholangiocarcinoma.

          2. Prior systemic therapy for advanced or metastatic biliary tract cancer. However, prior
             chemotherapy in the adjuvant setting or low-dose chemotherapy given in conjunction
             with radiotherapy in the adjuvant setting and completed at least 6 months prior to
             enrolment is permitted. The following prior interventions are allowed provided the
             patient has fully recovered:

               -  Surgery: non-curative resection with macroscopic residual disease or palliative
                  bypass surgery. Patients who have previously undergone curative surgery must now
                  have evidence of non-resectable disease requiring systemic chemotherapy.

               -  Radiotherapy: prior radiotherapy (with or without radio-sensitizing low-dose
                  chemotherapy) for localized disease and there is now clear evidence of disease
                  progression requiring systemic chemotherapy.

               -  Photodynamic therapy: prior photodynamic therapy for localized disease with no
                  evidence of metastatic disease or for localized disease to relieve biliary
                  obstruction in the presence of metastatic disease provided there is now clear
                  evidence of disease progression requiring systemic chemotherapy.

               -  Palliative radiotherapy: palliative radiotherapy provided that all adverse events
                  have resolved and the patient has measurable disease outside the field of
                  radiation.

          3. Prior treatment with or known hypersensitivity to NUC-1031, gemcitabine, cisplatin or
             other platinum-based agents or history of allergic reactions attributed to the
             excipients contained in NUC-1031 or diluent solution (dimethylacetamide [DMA],
             Kolliphor ELP, Tween 80).

          4. Symptomatic central nervous system or leptomeningeal metastases.

          5. History of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in situ cancer of the cervix, low grade prostate cancer not
             requiring treatment or other solid tumours curatively treated with no evidence of
             disease for ≥3 years.

          6. Concurrent serious (as deemed by the Investigator) medical conditions, including, but
             not limited to, New York Heart Association class III or IV congestive heart failure,
             history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis
             B or C, or other co-morbid conditions that in the opinion of the Investigator would
             impair study participation or cooperation.

          7. Congenital or acquired immunodeficiency (e.g., serious active infection with HIV). As
             per inclusion criterion 10, patients with HIV who are healthy and have a low risk of
             AIDS related outcomes are eligible.

          8. Other acute or chronic medical, neurological, or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the patient
             inappropriate for entry into this study.

          9. Prior exposure to another investigational agent within 28 days prior to randomization.

         10. Major surgery within 28 days prior to randomization; patient must have completely
             recovered from any prior surgical or other procedures.

         11. Pregnant or breastfeeding.

         12. Residual toxicities from prior treatments or procedures which have not regressed to
             Grade ≤1 severity (CTCAE v5.0), except for alopecia or ≤ Grade 2 peripheral
             neuropathy.

         13. Concomitant use of drugs at doses known to cause clinically relevant prolongation of
             QT/QTc interval.

         14. Administration of a live vaccination within 28 days prior to randomization.

         15. Ongoing or recent (≤6 months) hepatorenal syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Knox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine, University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew McKellar</last_name>
    <phone>+44 131 357 3950</phone>
    <email>Nutide121@nucana.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates , PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Kimbell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Daly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602-3171</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Caballero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP- Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne F Boynton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabel A Moya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ma Theresa De Leon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Scott</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliate Oncologists LLC</name>
      <address>
        <city>Chicago Ridge</city>
        <state>Illinois</state>
        <zip>60415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Brich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Roberts</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Roberts</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley O'Meara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Besaw</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hemtology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Rabenn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Research Foundation for The State University of New York</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-3369</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppina Caravella</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prisma Health Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Dean</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle L Owens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan B Huntzinger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lupe Madrid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasey Heil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.-Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zandra E McChesney</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital and Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane M Davis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquie Harvey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Charlton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanieh Fattahi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Townsville Cancer Centre</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Page</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warringal Medical Centre</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo Yuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Cross</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshmi Sharma-Diwakarla</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Damas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Besel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Ramnarine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzana Cernocka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johana Krempová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Simkova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice</name>
      <address>
        <city>Prague</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslava Skálová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Burgersteinová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margit Peters-Hornig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mészáros Brigitta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivien Garajszki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balogh Brigitta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ildiko Jakab</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szilvia Ligay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edina Bodor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Bruno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyunJung Jun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuk Hwa Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ha Ju Heon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seohee Seong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Ju Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Won Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhyeong Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minji Jo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Ji Heo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadeghda Kirillova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Beltran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izar Achaerandio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercè Garcia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Perez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gomez Crespo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Suengas MTZ De Ilarduya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Roncel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Medical Foundation Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>50004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin-Feng Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei-Chen Hsu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10016</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-Ju Liao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jui-Chuan Chin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling-Ling Chiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mediha Avci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baskent University Adana Application and Research Center</name>
      <address>
        <city>Adana</city>
        <zip>01220</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seyma Blir</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Faculty</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tugce Buket Guler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inonu Uni. Med. Fac.</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Refah Karatas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CI Chernivtsi RC Oncological Dispensary</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tashchuk Illya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv NMU</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kateryna Bukhtieieva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection</name>
      <address>
        <city>Kharkiv</city>
        <zip>61166</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliia Zekun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncological Center</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetyana Tymchuk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI &quot;Shalimov's National Institute of Surgery and Transplantation&quot; of NAMSU</name>
      <address>
        <city>Kyiv</city>
        <zip>03126</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksii Zubkov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Treatment-Prevention Institution Volyn Regional Oncological Dispensary</name>
      <address>
        <city>Luts'k</city>
        <zip>43018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serhii Kylynych</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Institution Odesa Regional Clinical Hospital</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Goloborodko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RCI Sumy Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Skrypnyk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE1 9RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susie Slater</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Cutting</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arielle Wilson-Dodard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Gourlay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre</name>
      <address>
        <city>Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Bygroves</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Ampullary</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Biliary Tract Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Distal Bile Duct</keyword>
  <keyword>Extrahepatic</keyword>
  <keyword>First-line Chemotherapy</keyword>
  <keyword>Gallbladder</keyword>
  <keyword>Gastrointestinal</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Hepatobiliary</keyword>
  <keyword>Intrahepatic</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>NUC-1031</keyword>
  <keyword>ProTides</keyword>
  <keyword>Untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

